lymphoma news from FierceBiotech
News
Following trial failure, Favrille cuts staff
San Diego's Favrille is making massive cuts following the trial failure of Specifid announced earlier this week. The company is axing 132 of its 144 employees, including six of its eight executive Read more...
Favrille dumps Specifid after trial failure
San Diego-based Favrille has halted development of Specifid, a treatment for follicular B-cell non-Hodgkin's lymphoma. In a Phase III trial the drug failed to show a statistically significant Read more...
Rituxan fails (again) in late-stage lupus trial
Genentech and Biogen Idec were taking it on the chin this morning after researchers announced that Rituxan had failed in a later-stage trial as a therapy for lupus. The failure won't harm the Read more...
Genitope suspends cancer work, looks to alternatives
After reviewing a failed late-stage trial of MyVax for Hodgkins lymphoma, Genitope has decided to suspend development work and focus on alternatives like its antibody program. MyVax had already Read more...
Amgen inks $520M deal with Kyowa Hakko
Amgen has inked a $520 million deal to acquire Kyowa Hakko's humanized monoclonal antibody (MAb) KW-0761, a treatment for inflammation and oncology settings. Tokyo-based Kyowa Hakko gains $100 Read more...
EUSA, GSK ink $44M pre-clinical antibody deal
EUSA Pharma will keep about half of the $44 million in up front fees and milestones it is scheduled to receive from GlaxoSmithKline for a license covering a pre-clinical antibody targeted at lymphoma Read more...
Novacea slows down development program for AQ4N
Novacea, which is burning through $17 million to $19 million this year, says it will scale back on the development of AQ4N, shelving a clinical trial in acute lymphoblastic leukemia and delaying a Read more...
Santaris grabs $30M in third round venture cash
Denmark's Santaris Pharma has banked $30 million from its latest venture round. Gilde Healthcare Partners put up much of that money with BankInvest, Novo, LD, Forbion Capital Partners, Global Life Read more...
BioCryst halts leukemia trial
BioCryst has discontinued a Phase IIb trial of intravenous Forodesine HCl in patients with T-cell acute lymphoblastic leukemia/lymphoma. The decision to discontinue the trial was based on a number of Read more...
Sources: Biogen gets bidders, with Pfizer in lead
The Financial Times is reporting some tantalizing details about the bidding for Biogen Idec, the biotech based in Cambridge, MA, that Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets